This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Edgemont Pharmaceuticals, LLC

Drug Names(s): CPI-300, bupropion hydrochloride, Forfivo XL

Description: CPI-300 was formulated using IntelGenx’s proprietary controlled release technology. It contains a new strength of the antidepressant bupropion. CPI-300 was developed to broaden the dosing options for physicians while providing a more convenient dosing option for patients requiring a higher strength of the products currently available.

Deal Structure: IntelGenx and Cary
In April 2008, IntelGenx and Cary Pharmaceuticals ratified the Definitive Agreement originally signed on November 5, 2007 to jointly develop and commercialize Carys oral antidepressant, CPI-300, using IntelGenxs proprietary oral delivery technology. Under the terms of the Agreement, IntelGenx secured funding of $2 million for the completion of the product development after closing a private placement worth $2.8 million on March 27, 2008. IntelGenx will be entitled to profit sharing.

In May 2010, IntelGenx executed a Project Transfer Agreement with Cary, whereby Cary assigned its 50% ownership stake in CPI-300 to IntelGenx and agreed that the CPI-300 project will be transferred to IntelGenx. IntelGenx will pay Cary, upon commercialization of CPI-300, 10% of sales royalties received by IntelGenx and 3% of upfront payments received by IntelGenx should a distribution agreement be signed in the future.

IntelGenx and Edgemont
In...See full deal structure in Biomedtracker

Partners: Cary Pharmaceuticals SWK Holdings Corporation IntelGenx Technologies Corp.

Forfivo News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug